Indaptus Therapeutics, Inc. (INDP): Shareholders' Equity
$3.15M
As of 2025-12-31
$11.37M
As of 2026-06-30
-49.6%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.15M | -20.1% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $3.94M | -67.3% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $12.08M | -51.0% | 2025-03-13, Balance as of period end |
| 2022-12-31 | $24.63M | -31.4% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $35.90M | n/m | 2023-03-17, Balance as of period end |
| 2020-12-31 | -$237.7K | n/a | 2022-03-21, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | 2025-12-31 | $3.15M | -20.1% |
| Soligenix, Inc. (SNGX) | 2025-12-31 | $5.29M | +28.5% |
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | -$1.26M | n/m |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $7.00M | -43.3% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $5.59M | +2.9% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $6.16M | +125.1% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $7.01M | +82.0% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $2.38M | -34.6% |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $6.33M | -33.5% |
Compare INDP, SNGX, PMN, KALA side by side · Screen every company in Pharmaceutical Preparations ↗